5:01 Acquisition Corp
NASDAQ:FVAM
Intrinsic Value
5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or simi... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FVAM.
Fundamental Analysis
Balance Sheet Decomposition
5:01 Acquisition Corp
Current Assets | 739k |
Cash & Short-Term Investments | 674.1k |
Other Current Assets | 64.9k |
Non-Current Assets | 82.7m |
Long-Term Investments | 82.7m |
Current Liabilities | 274.6k |
Accounts Payable | 149.6k |
Accrued Liabilities | 125k |
Non-Current Liabilities | 3.9m |
Other Non-Current Liabilities | 3.9m |
Earnings Waterfall
5:01 Acquisition Corp
Revenue
|
0
USD
|
Operating Expenses
|
-1.3m
USD
|
Operating Income
|
-1.3m
USD
|
Other Expenses
|
130.8k
USD
|
Net Income
|
-1.2m
USD
|
Free Cash Flow Analysis
5:01 Acquisition Corp
FVAM Profitability Score
Profitability Due Diligence
5:01 Acquisition Corp's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
5:01 Acquisition Corp's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
FVAM Solvency Score
Solvency Due Diligence
5:01 Acquisition Corp's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
5:01 Acquisition Corp's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FVAM Price Targets Summary
5:01 Acquisition Corp
Shareholder Return
FVAM Price
5:01 Acquisition Corp
Average Annual Return | 3.5% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -15% |
Market Capitalization | 106.6m USD |
Shares Outstanding | 10 656 718 |
Percentage of Shares Shorted | 0.08% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company is headquartered in San Francisco, California. The company went IPO on 2020-10-14. The firm is created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The firm focuses on early stage North American or European companies in the biotechnology sector of the healthcare industry. The firm has no operations and has not generated revenues.